Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Asymptomatic cardiac ischemia pilot (ACIP)

C R Conti1, M G Bourassa, B R Chaitman

  • 1Department of Medicine, University of Florida, College of Medicine, Gainesville, USA.

Transactions of the American Clinical and Climatological Association
|January 1, 1994
PubMed
Summary

This pilot study shows that medical or revascularization strategies can manage asymptomatic cardiac ischemia in coronary artery disease (CAD) patients. Revascularization effectively reduced ischemia, but long-term costs and outcomes require further large-scale clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina.

Clinical pharmacology and therapeutics·2012
Same author

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study.

American heart journal·2001
Same author

Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release: results from the GUARDIAN trial.

Journal of the American College of Cardiology·2001
Same author

Atorvastatin for acute coronary syndromes.

JAMA·2001
Same author

Risk stratification after successful coronary revascularization: the lack of a role for routine exercise testing.

Journal of the American College of Cardiology·2001
Same author

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

JAMA·2001

Area of Science:

  • Cardiology
  • Clinical Trials
  • Medical Economics

Background:

  • Coronary artery disease (CAD) patients with asymptomatic cardiac ischemia present complex management challenges.
  • The economic implications of treating asymptomatic ischemia are substantial, with potential long-term cost advantages if adverse events are reduced.

Purpose of the Study:

  • To assess the feasibility of randomizing patients with CAD and asymptomatic cardiac ischemia to medical or revascularization strategies.
  • To evaluate the effectiveness of medical therapy in suppressing asymptomatic cardiac ischemia.
  • To compare the efficacy of different treatment strategies in reducing cardiac ischemia.

Main Methods:

  • A pilot study involving a complex randomization protocol for patients with CAD and asymptomatic cardiac ischemia.

Related Experiment Videos

  • Titration of low to moderate doses of medication over 12 weeks to suppress ischemia.
  • Comparison of medical therapy versus revascularization strategies.

    • Main Results:

    • Successful randomization of patients to medical or revascularization groups was demonstrated.
    • Medication suppressed asymptomatic cardiac ischemia in 40-50% of patients within 12 weeks.
    • Revascularization emerged as the most effective strategy for reducing ischemia in this pilot study.

    Conclusions:

    • Managing asymptomatic cardiac ischemia in CAD patients is feasible through randomized trials.
    • Revascularization is highly effective in reducing ischemia, though long-term cost-effectiveness and impact on adverse events remain key questions.
    • Large-scale clinical trials are necessary to determine optimal therapeutic strategies for reducing cardiac events and guiding future healthcare economic decisions.